Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227564 · ClinicalTrials.gov registry record · Phase 2
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01227564 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 63 participants.
The verdict
NCT01227564, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
Interventions
- BIOLOGICAL ACC-001 3 μg/ QS-21 50 μg
- BIOLOGICAL ACC-001 10 μg/ QS-21 50 μg
- OTHER Placebo- Phosphate buffered saline (PBS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01227564
The ClinicalTrials.gov registry entry for NCT01227564 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ACC-001 3 μg/ QS-21 50 μg is the first listed.
NCT01227564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01227564 about?
NCT01227564 is a clinical study titled "Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease". This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography (PET) scans.
What is the current status of trial NCT01227564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2011-02. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01227564?
The interventions under investigation include: ACC-001 3 μg/ QS-21 50 μg (BIOLOGICAL), ACC-001 10 μg/ QS-21 50 μg (BIOLOGICAL), Placebo- Phosphate buffered saline (PBS) (OTHER).
Who is sponsoring clinical trial NCT01227564?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.